TY - JOUR
T1 - Nitric oxide
T2 - A clinically important amniotic fluid marker to distinguish between intra-amniotic mycoplasma and non-mycoplasma infections
AU - Hsu, Chaur Dong
AU - Aversa, Kristen R.
AU - Lu, Li Cheng
AU - Meaddough, Erika
AU - Jones, David
AU - Bahado-Singh, Ray O.
AU - Copel, Joshua A.
AU - Lee, In Sik
PY - 1999
Y1 - 1999
N2 - The objective of this study was to determine whether the measurements of amniotic fluid nitric oxide metabolite (NOx: nitrate + nitrite) concentrations could be a clinically useful marker to differentiate between intra-amniotic mycoplasma and nonmycoplasma infections. Amniocentesis was performed on 76 pregnant women with suspicion of intra-amniotic infection. Intra-amniotic infection was defined as the presence of a positive amniotic fluid culture with either mycoplasma or nonmycoplasma infections. Rapid amniotic fluid tests for Gram stain, glucose, leukocyte counts, interleukin- 6, and NOx were performed. Amniotic fluid NOx was measured with aspergillus nitrate reductase and Griess reagent. Interleukin-6 was determined by enzyme immunoassays. Amniotic fluid NOx and interleukin-6 were normalized by amniotic fluid creatinine levels. Patients with intra-amniotic mycoplasma (n = 7) and nonmycoplasma infections (n = 8) had significantly higher amniotic fluid leukocyte counts and interleukin-6 concentrations and significantly lower amniotic fluid glucose levels than noninfected controls (n = 61). Amniotic fluid concentrations of NOx were significantly higher in those with intraamniotic nonmycoplasma infection as compared to those with intraamniotic mycoplasma infection and noninfected controls (NOx: 3.35 ± 0.74 vs. 2.03 ± 0,41 μmol/mg creatinine, p = 0.005, and 3.35 ± 0.74 vs. 1.72 ± 0.07 μmol/mg creatinine, p < 0.0001, respectively). However, patients with intra- amniotic mycoplasma infection did not differ significantly from noninfected controls. Our data indicate that clinical characteristics of intra-amniotic mycoplasma infection may differ from intra-amniotic nonmycoplasma infection. As delivery is not always indicated in intra-amniotic mycoplasma infection, elevated rapid amniotic fluid tests (leukocyte counts, interleukin-6, and glucose) may not be appropriate in the clinical management of intra-amniotic mycoplasma infection. In addition to these rapid amniotic fluid tests, incorporation of the measurement of amniotic fluid NOx may be of clinical importance in the differentiation and management of patients with suspected intra-amniotic mycoplasma and nonmycoplasma infection.
AB - The objective of this study was to determine whether the measurements of amniotic fluid nitric oxide metabolite (NOx: nitrate + nitrite) concentrations could be a clinically useful marker to differentiate between intra-amniotic mycoplasma and nonmycoplasma infections. Amniocentesis was performed on 76 pregnant women with suspicion of intra-amniotic infection. Intra-amniotic infection was defined as the presence of a positive amniotic fluid culture with either mycoplasma or nonmycoplasma infections. Rapid amniotic fluid tests for Gram stain, glucose, leukocyte counts, interleukin- 6, and NOx were performed. Amniotic fluid NOx was measured with aspergillus nitrate reductase and Griess reagent. Interleukin-6 was determined by enzyme immunoassays. Amniotic fluid NOx and interleukin-6 were normalized by amniotic fluid creatinine levels. Patients with intra-amniotic mycoplasma (n = 7) and nonmycoplasma infections (n = 8) had significantly higher amniotic fluid leukocyte counts and interleukin-6 concentrations and significantly lower amniotic fluid glucose levels than noninfected controls (n = 61). Amniotic fluid concentrations of NOx were significantly higher in those with intraamniotic nonmycoplasma infection as compared to those with intraamniotic mycoplasma infection and noninfected controls (NOx: 3.35 ± 0.74 vs. 2.03 ± 0,41 μmol/mg creatinine, p = 0.005, and 3.35 ± 0.74 vs. 1.72 ± 0.07 μmol/mg creatinine, p < 0.0001, respectively). However, patients with intra- amniotic mycoplasma infection did not differ significantly from noninfected controls. Our data indicate that clinical characteristics of intra-amniotic mycoplasma infection may differ from intra-amniotic nonmycoplasma infection. As delivery is not always indicated in intra-amniotic mycoplasma infection, elevated rapid amniotic fluid tests (leukocyte counts, interleukin-6, and glucose) may not be appropriate in the clinical management of intra-amniotic mycoplasma infection. In addition to these rapid amniotic fluid tests, incorporation of the measurement of amniotic fluid NOx may be of clinical importance in the differentiation and management of patients with suspected intra-amniotic mycoplasma and nonmycoplasma infection.
KW - Amniotic fluid
KW - Interleukin-6
KW - Intra-amniotic infection
KW - Mycoplasma
KW - Nitric oxide
UR - http://www.scopus.com/inward/record.url?scp=0032777071&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032777071&partnerID=8YFLogxK
U2 - 10.1055/s-2007-993851
DO - 10.1055/s-2007-993851
M3 - Article
C2 - 10458527
AN - SCOPUS:0032777071
SN - 0735-1631
VL - 16
SP - 161
EP - 166
JO - American Journal of Perinatology
JF - American Journal of Perinatology
IS - 4
ER -